NCT04042558 - A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

September 26, 2019

Primary Completion Date

October 22, 2021

Study Completion Date

April 9, 2025

Conditions

NSCLC Stage IIIBNSCLC Stage IVEGFR Gene MutationALK Gene Rearrangement PositiveROS1 Gene Mutation

Interventions

DRUG

Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab

4 cycles of induction every 3 weeks of cisplatine,pemetrexed, atezolizumab + bevacizumab and patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed +/- Bevacizumab administered at the same dosage on 3-week cycles

DRUG

Carboplatin + Pemetrexed + Atezolizumab

Trial Locations (31)

14076

Centre François Baclesse, Caen

Unknown

CHU, Angers

Centre Hospitalier, Annecy

CHU-Hôpital MORVAN, Brest

CHU Lyon Louis Pradel, Bron

CHU Gabriel MONTPIED, Clermont-Ferrand

CHIC, Créteil

CHU, Grenoble

CHU Réunion St Denis, La Réunion

CHU Réunion St Pierre, La Réunion

CHD Vendée La Roche sur Yon, La Roche-sur-Yon

CHU, Lille

CHU Limoges, Limoges

Centre Léon Bérard, Lyon

CHU Lyon, Croix-Rousse,, Lyon

Hôpital Nord, Marseille

CHR Orléans, Orléans

Hopital Foch, Paris

institut Curie, Paris

HIA Percy, Percy

Hôpital Haut Lévêque,Centre François Magendie, Pessac

CHU, Pierre-Bénite

CHU, Rennes

CHU, Rouen

ICLN, St Priez en Jarez, Saint-Priest-en-Jarez

Centre Paul Strauss, Strasbourg

HIA St Anne, Toulon

CHU, Toulouse

Centre Hospitalier Bretagne Atlantique, Vannes

Centre Hospitalier, Villefranche

HIA R.Picqué, Villenave-d'Ornon

All Listed Sponsors

collaborator

GFPC

UNKNOWN

lead

Centre Francois Baclesse

OTHER